Waltham, MA and Shanghai, China 11/13/12—PerkinElmer has acquired China-based Shanghai Haoyuan Biotech, an infectious disease diagnostics company, for $38 million in cash and potential future additional consideration. The company supplies molecular infectious disease screening technologies for blood banks and clinical labs in China. The acquisition extends PerkinElmer’s capabilities into nucleic acid blood screening and molecular clinical diagnostics in China, adding four infectious disease assays that are approved by China’s State Food and Drug Administration. “By combining PerkinElmer’s robust disease screening capabilities with Haoyuan’s proprietary reagents and equipment, the Company will be able to offer highly sensitive systems and assays for quality detection of blood-borne infections for the Chinese market,” commented Robert Friel, chairman and CEO of PerkinElmer. The acquisition is expected to be immaterial to adjusted earnings for the remainder of 2012 and 2013 and accretive in 2014.